Differences in human phospholipid transfer protein activity following incubation of Fungizone® compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma

References

• Siggins S. (2005). Plasma phospholipid transfer protein (PLTP): quantitation, biosynthesis, and involvement in hepatic lipid homeostasis, National Public Health Institute - Kanasanterveyslaitos (KTL), September 16.
   Google Scholar
• Tan KC, Shiu SW, Wong Y, Tam S. (2005). Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis, 178:365–70.
   PubMed Web of Science ®Google Scholar
• Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M. (2006). Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res, 47:1725–32.
   PubMed Web of Science ®Google Scholar
• Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. (2001). The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis, 155:269–81.
   PubMed Web of Science ®Google Scholar
• Huuskonen J, Wohlfahrt G, Jauhiainen M, Ehnholm C, Teleman O, Olkkonen VM. (1999). Structure and phospholipid transfer activity of human PLTP: Analysis by molecular modeling and site-directed mutagenesis. J Lipid Res, 40:1123–30.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Albers JJ. (2006). Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins. J Lipid Res, 47:1315–21.
   PubMed Web of Science ®Google Scholar
• Janis MT, Metso J, Lankinen H, Strandin T, Olkkonen VM, Rye KA, . (2005). Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun, 331:333–40.
   PubMed Web of Science ®Google Scholar
• van TA. (2002). Phospholipid transfer protein. Curr Opin Lipidol, 13:135–9.
   PubMed Web of Science ®Google Scholar
• Vikstedt R, Metso J, Hakala J, Olkkonen VM, Ehnholm C, Jauhiainen M. (2007). Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. Biochemistry, 46:11979–86.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Brown BG, Marino Larsen EK, Frutkin AD, O'Brien KD, Albers JJ. (2006). Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta, 1762:131–7.
   PubMed Web of Science ®Google Scholar
• Tall AR, Lalanne F. (2003). Phospholipid transfer protein and atherosclerosis. Arterioscler Thromb Vasc Biol, 23:1484–5.
   PubMed Web of Science ®Google Scholar
• Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y, . (2003). Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res, 44:1256–62.
   PubMed Web of Science ®Google Scholar
• Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, . (2001). Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med, 7:847–52.
   PubMed Web of Science ®Google Scholar
• Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC. (2007). Macrophage phospholipid transfer protein deficiency and ApoE secretion: Impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol, 27:190–6.
   PubMed Web of Science ®Google Scholar
• Paszty C, Maeda N, Verstuyft J, Rubin EM. (1994). Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest, 94:899–903.
   PubMed Web of Science ®Google Scholar
• Schgoer W, Mueller T, Jauhiainen M, Wehinger A, Gander R, Tancevski I, . (2008). Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis, 196:219–26.
   PubMed Web of Science ®Google Scholar
• Sivak O, Lau B, Patankar N, Wasan KM. (2004). Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex. Pharm Res, 21:2336–9.
   PubMed Web of Science ®Google Scholar
• Patankar N, Wasan KM. (2006). Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations. Pharm Res, 23(5):1020–4.
   PubMed Web of Science ®Google Scholar
• Oka T, Kujiraoka T, Ito M, Nagano M, Ishihara M, Iwasaki T, . (2000). Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin Chem, 46:1357–64.
   PubMed Web of Science ®Google Scholar
• Bekersky II, Fielding RM, Buell D, Lawrence II. (1999). Lipid-based amphotericin B formulations: From animals to man. Pharm Sci Technol Today, 2:230–6.
   PubMedGoogle Scholar
• Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. (2002). Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother, 46:828–33.
   PubMed Web of Science ®Google Scholar
• Dullaart RP, De VR, Scheek L, Borggreve SE, Van GT, linga-Thie GM, . (2004). Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest, 64:205–15.
   PubMed Web of Science ®Google Scholar
• linga-Thie GM, van TA, Hattori H, Rensen PC, Sijbrands EJ. (2006). Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?. Diabetes, 55:1491–6.
   PubMed Web of Science ®Google Scholar
• O'Keefe JHJr, Captain BK, Jones PG, Harris WS. (2004). Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol, 7:154–60.
   PubMedGoogle Scholar
• Murdoch SJ, Kahn SE, Albers JJ, Brunzell JD, Purnell JQ. (2003). PLTP activity decreases with weight loss: Changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. J Lipid Res, 44:1705–12.
   PubMed Web of Science ®Google Scholar